Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

por Seymour, John F.
Publicado 2022

Choosing between family members is always a balancing act

por Bennett, Rory, Seymour, John F.
Publicado 2023

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

por Lew, Thomas E., Seymour, John F.
Publicado 2022

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia

por Bennett, Rory, Anderson, Mary Ann, Seymour, John F.
Publicado 2023

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

por Minson, Adrian, Tam, Constantine, Dickinson, Michael, Seymour, John F.
Publicado 2022

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

por Lew, Thomas E., Anderson, Mary Ann, Seymour, John F.
Publicado 2020

Zanubrutinib: past, present, and future

por Tam, Constantine S., Muñoz, Javier L., Seymour, John F., Opat, Stephen
Publicado 2023

Correction: Zanubrutinib: past, present, and future

por Tam, Constantine S., Muñoz, Javier L., Seymour, John F., Opat, Stephen
Publicado 2023

Overview of early response assessment in lymphoma with FDG-PET

por MacManus, Michael P, Seymour, John F, Hicks, Rodney J
Publicado 2007

Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail

por Essakali, Salim, Carney, Dennis, Westerman, David, Gambell, Peter, Seymour, John F, Dobrovic, Alexander
Publicado 2008

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

por Tiong, Ing S., Reynolds, John, Bradstock, Kenneth F., Seymour, John F., Wei, Andrew H.
Publicado 2018

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

por Tiong, Ing S., Stevenson, William S., Wall, Meaghan, Yap, Yan Zhuang, Seymour, John F., Kenealy, Melita, Blombery, Piers
Publicado 2023

Detection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia

por Tan, Angela YC, Westerman, David A, Carney, Dennis A, Seymour, John F, Juneja, Surender, Dobrovic, Alexander
Publicado 2008

The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug cli...

por Russell, Lahiru, Pascoe, Michaela C., Seymour, John F., Aranda, Sanchia, Butow, Phyllis, Gough, Karla, Schofield, Penelope
Publicado 2019

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute...

por Bradstock, Kenneth F., Morley, Alec, Byth, Karen, Szer, Jeff, Prosser, Ian, Cannell, Paul, Irving, Ian, Seymour, John F.
Publicado 2016

A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies

por Chait-Rubinek, Lori, Mariani, Justin A., Goroncy, Natalie, Herschtal, Alan, Wheeler, Greg C., Dwyer, Mary K., Seymour, John F., Campbell, Belinda A.
Publicado 2019

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment f...

por Mir, Farheen, Mattiello, Federico, Grigg, Andrew, Herold, Michael, Hiddemann, Wolfgang, Marcus, Robert, Seymour, John F., Bolen, Christopher R., Knapp, Andrea, Nielsen, Tina, Casulo, Carla
Publicado 2020

Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy

por MacManus, Michael P., Hicks, Rodney J., Bressel, Mathias, Campbell, Belinda A., Wirth, Andrew, Ryan, Gail, Prince, H. Miles, Wolf, Max, Brown, Rachel, Seymour, John F.
Publicado 2020

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase...

por Mato, Anthony R., Sharman, Jeff P., Biondo, Juliana M.L., Wu, Mei, Mun, Yong, Kim, Su Y., Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F.
Publicado 2020

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

por Kim, Sang-Kyu, Knight, Deborah A., Jones, Lisa R., Vervoort, Stephin, Ng, Ashley P., Seymour, John F., Bradner, James E., Waibel, Michaela, Kats, Lev, Johnstone, Ricky W.
Publicado 2018